24,25-oxidolanosterol has been researched along with olanzapine in 1 studies
Studies (24,25-oxidolanosterol) | Trials (24,25-oxidolanosterol) | Recent Studies (post-2010) (24,25-oxidolanosterol) | Studies (olanzapine) | Trials (olanzapine) | Recent Studies (post-2010) (olanzapine) |
---|---|---|---|---|---|
7 | 0 | 1 | 6,339 | 1,340 | 2,383 |
Protein | Taxonomy | 24,25-oxidolanosterol (IC50) | olanzapine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.097 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.155 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.047 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.04 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.541 | |
Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.768 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.118 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.047 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.421 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.531 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.392 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.072 | |
D(4) dopamine receptor | Homo sapiens (human) | 0.173 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.092 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.021 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.047 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.033 | |
Histamine H1 receptor | Homo sapiens (human) | 0.013 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.078 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.057 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.013 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.158 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2028 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Guo, F; Hu, J; Ouyang, H; Qiu, X; Tan, Y; Wu, S | 1 |
1 other study(ies) available for 24,25-oxidolanosterol and olanzapine
Article | Year |
---|---|
Improved biopharmaceutical performance of antipsychotic drug using lipid nanoparticles via intraperitoneal route.
Topics: Animals; Antipsychotic Agents; Biological Products; Cyclooxygenase 2; Delayed-Action Preparations; Drug Carriers; Lanosterol; Lipopolysaccharides; Liposomes; Mice; Nanoparticles; NF-kappa B; Olanzapine; Particle Size; Suspensions | 2022 |